Drug development

#Antibodies #Drug development #Drug discovery #Huntington's disease

Collaboration to develop landmark novel antibody therapy for Huntington’s

Alchemab, a biotech company harnessing the power of naturally protective antibodies, has been awarded a UK Biomedical Catalyst early award grant from Innovate UK to support its collaboration with Medicines Discovery Catapult and the development of a novel disease-modifying antibody therapy for Huntington’s disease. Using its novel approach, Alchemab has… Read More

#News

#Drug delivery #Drug development #Drug discovery

Horizon Therapeutics acquires Viela Bio

Discovery, development and commercialisation company Horizon Therapeutics has announced the completion of the acquisition of drug developer, Viela Bio. Tim Walbert, chairman, president and chief executive officer, Horizon, said: “With its deep, mid-stage biologics pipeline, strong R&D team and on-market medicine UPLIZNA, Viela is a strong complementary strategic fit with… Read More

#News

#Alzheimer's #Dementia #Drug development #Drug discovery

Researchers discover critical step in formation of fatal brain diseases

A research team from Imperial College London and the University of Zurich have identified what causes normal proteins to convert to diseased form, causing conditions like Creutzfeldt-Jakob disease (CJD) and Kuru. The researchers also tested a way to block the process, which could lead to new drugs for combatting such… Read More

#News

#Drug delivery #Drug development #Drug discovery #Parkinson's

Researchers collaborate to design treatment for Parkinson’s disease

‍IRICoR, a pan-Canadian drug discovery and research commercialisation centre, Université de Montréal (UdeM), the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, and Valence Discovery, AI-enabled drug designer, have announced a collaboration focussing on the discovery of novel drug candidates for the treatment of levodopa-induced dyskinesia… Read More

#Editor's Choice #News #Trending News

#Diabetes #Drug development #Drug discovery #Research study #Type 2 diabetes

Two new diabetes drugs may work better for Asian people

According to new research, two new but commonly-used diabetes drugs, one of which is also now approved for use in heart failure in people with or without diabetes, might be more effective in people with an Asian background than in people with a White… Read More

#News

#Covid-19 #Drug development #Drug discovery #Research study #Study

UK researchers identify inflammatory protein linked to severe COVID-19

Patients with severe COVID-19 show increased levels of a key protein in their blood, which researchers believe may help identify those most at risk. In an analysis of more than 500 COVID-19 patients across the UK, researchers identified several inflammatory markers in blood which increased within the early stages of… Read More

#Covid-19 #News

#Biotechnology #Drug development #Molecular research

AMRI scoops Forbes’ best employer accolade

Albany Molecular Research (AMRI), provider of advanced contract research, development and manufacturing solutions, has been included in America’s Best Employers 2021 list, published by Forbes. AMRI was included in the Drugs and Biotechnology industry category of the ranking. Its 3,100 employees provide scientific solutions across the R&D and manufacturing continuum… Read More

#News

#AstraZeneca #Covid-19 #Drug development #Immunology / Virology & Vaccines #Moderna #Pfizer

COVID-19 booster shots more likely than vaccines due to variants

Data analytics company, GlobalData says that if new SARS-CoV-2 variants continue to develop, reducing the effectiveness of COVID-19 vaccines and the natural immunity of survivors, then annual booster shots may be required for COVID-19 immunity. Johanna Swanson, Product Manager at GlobalData, said: “Of the several natural variants that have recently been… Read More

#Covid-19 #News

#Cancer research #Diagnostics #Drug development #In vitro

Avacta enters diagnostic licensing deal with Biokit

Avacta, developer of cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms, has announced a licensing agreement with Biokit, to incorporate Affimer reagents into a Biokit in-vitro diagnostic (IVD) product. Biokit has experience in research, development and manufacturing of assays and biomaterial solutions for IVD use. Under… Read More

#Cancer Research #News

#Brain disease #Drug development #Drug discovery #Screening

Human cerebral organoid used to test drug for fatal brain disease

After establishing a human cerebral organoid system to study Creutzfeldt-Jakob disease (CJD), National Institutes of Health researchers have further developed the model to screen drugs for potential CJD treatment. CJD, a fatal neurodegenerative brain disease of humans caused by infectious prion proteins, affects about 1 in a million people annually. Read More

#News

#Cancer research #Drug development #Drug discovery #Genes

New study able to detect BRCA1 breast cells before they turn cancerous

The earliest changes that occur in seemingly healthy breast tissue before tumours appear may have been found by researchers, suggests a new study published in Nature Communications. The study in mice, funded by Cancer Research UK, showed that before becoming cancerous, breast cells with the BRCA1 gene mutation undergo changes similar… Read More

#Cancer Research #News

#Biologics / Biotechnology #Cancer immunotherapy #Cancer research #Drug development

Pathios Therapeutics boosted with Innovate UK funding

Pathios, a biotech company focused on the development of first-in-class therapies for cancer, announced that it has been awarded £350K in the form of a Smart Grant from Innovate UK. The UK government innovation agency’s money will accelerate Pathios’ cancer immunotherapy programme which targets the innate immune checkpoint, GPR65. Pathios… Read More

#Cancer Research #News

#Biopharmaceuticals #Biotechnology #Drug delivery #Drug development

Amryt and Medison distribution agreement for metreleptin in Canada

Global biopharmaceutical company Amryt has signed a distribution agreement with Medison Pharma Canada to distribute Myalepta (metreleptin) in Canada. Amryt is a global, commercial-stage biopharmaceutical company focused on acquiring, developing and commercialising novel treatments for rare diseases. Medison is a commercial partner of global biotech companies that provide integrated services… Read More

#News

#AstraZeneca #Biopharmaceuticals #Drug delivery #Drug development

Aptamer Group extends AstraZeneca collaboration

UK reagents and therapeutics developer, Aptamer Group has extended its current agreement with global biopharmaceutical company AstraZeneca. This agreement will build upon the existing collaboration to evaluate the potential of using Optimer-based strategies to target renal cells and explore the feasibility of developing next-generation drug delivery vehicles, Optimer-drug conjugates. Optimers… Read More

#Editor's Choice #News #Trending News

#Biomarkers #Clinical trials #Drug development #Metabolomics #Metabolon

Life science companies collaborate for drug development

Metabolon and Cleveland Clinic have entered into multi-year collaborative agreement to accelerate research, drug development and precision medicine. Metabolon will leverage its proprietary platform to analyse a range of biologic samples to help discover metabolomic biomarkers that will deepen understanding of Cleveland Clinic’s novel discoveries, improve speed of decision-making and… Read More

#News